|
|
|
|
| LEADER |
01333nam a2200253 u 4500 |
| 001 |
EB002001600 |
| 003 |
EBX01000000000000001164501 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Tran, Khai
|
| 245 |
0 |
0 |
|a Ketamine for chronic non-cancer pain
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c authors, Khai Tran, Suzanne McCormack
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c 2020, May 28, 2020
|
| 300 |
|
|
|a 1 PDF file (28 pages)
|b illustration
|
| 700 |
1 |
|
|a McCormack, Suzanne
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK564230
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aim of this report is to review the evidence regarding the clinical effectiveness and cost-effectiveness of ketamine for treating chronic non-cancer pain in adults. This report also aims to review the evidence-based guidelines regarding the use of ketamine for chronic non-cancer pain
|